We offer a one-year immuno-oncology research fellowship for physicians interested in immuno-oncology. This fellowship can be completed independently of clinical training or as an additional year added to one of our surgical fellowship programs. This fellowship is ideal for recent medical or surgical oncology fellowship graduates, or internal medicine or surgery residency graduates who wish to pursue formal subspecialty training in medical / surgical oncology and desire focused training in immunology, immunotherapy and translational clinical trials to enhance an academic career path.

Earle A. Chiles Research Institute is the research arm of Providence Cancer Institute, a leader in immuno-oncology and home to a team of world-renowned scientists and physicians. With expertise in immunotherapy, basic, clinical and translational research and bioinformatics, it provides a rich learning environment for our immuno-oncology research fellows.

The purpose of the immuno-oncology research fellowship is to provide structured education and training to facilitate expertise in clinical immunotherapeutics for the treatment of cancer, and to provide a foundation in research methodology that will equip the fellow for a successful academic career in immuno-oncology.

Key program elements:

• Fellows will rotate in our medical oncology clinic, inpatient biotherapy service (includes adoptive cellular immunotherapy, experimental therapeutics and high-dose IL-2), immune monitoring laboratory and clinical trials.
• Training and mentorship is provided by world renowned leaders in the field of immuno-oncology including one-on-one discussion and teaching sessions
• The majority of fellow’s time will be spent conducting mentored, independent research in immuno-oncology with the expectation of publication and/or presentation at national meetings.
• I-O fellows can customize their curriculum with faculty mentorship to participate in basic laboratory and/or patient care activities.

Why Providence?

• Earle A. Chiles Research Institute, the research arm of Providence Cancer Institute is a global leader in immunotherapy. Our facility houses 45,000 square feet of dedicated research space and clinical manufacturing facilities. We have the benefit of the most advanced equipment and technology available in immunological monitoring, flow cytometry, immunohistology, molecular pathology and bioinformatics services.
• Cutting edge research, like being home to the first research laboratory in Oregon for adoptive cellular therapy – a highly personalized type of cancer immunotherapy that enhances a patient’s cancer-fighting immune cells in a laboratory and returns them to the patient in greater numbers and potency. We are also among the elite centers capable of administering advanced cellular therapies such as chimeric antigen receptor (CAR) T-cell therapy, tumor infiltrating lymphocytes (TIL) and high-dose interleukin-2 (IL-2).